Back to search
FDAFDA · Food and drugs·Recall number D-0649-2017

RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60

Published April 12, 2017 · Recall initiated: March 6, 2017

Summary

FDA records drug Class III recall D-0649-2017, published April 12, 2017 and initiated March 6, 2017. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 1,728 bottles; Lot: Lot #C607323, Exp 10/18. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.

What to do

Voluntary: Firm initiated · Letter

Get an email if RIVASTIGMINE TARTRATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
RIVASTIGMINE TARTRATE
Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
U.S. nationwide
Lot
Lot #C607323, Exp 10/18
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60 recalled?

Yes. FDA published recall D-0649-2017 on April 12, 2017. Reported hazard: Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: RIVASTIGMINE TARTRATE.